Valneva SE (INRLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved ... [Yahoo! Finance]
Valneva SE - American Depositary Shares (VALN)
Company Research
Source: Yahoo! Finance
IXIARO Gross Margin: 58.8% compared to 47.2% one year ago. DUKORAL Sales: EUR22.3 million, a 6% increase year over year. Chikungunya Vaccine Sales: EUR1.8 million in the United States by September 30th. Operating Profit: EUR34.2 million versus an operating loss of minus EUR57.2 million in the prior year. Adjusted EBITDA: Improved from minus EUR46 million to positive EUR48.6 million. Cash Position: EUR156.3 million as of September 30th. R&D Expense: Increased to EUR48.6 million from EUR42.2 million in the prior year. Marketing and Distribution Expense: Increased by 5% to EUR35.7 million. General and Administrative Expense: Decreased by 7% to EUR32.6 million. Sale of PRV Income: EUR90.8 million. Cash Use in Operating Activities: Decreased from EUR136 million to EUR76.7 million. Guidance for Product Sales: Narrowed to EUR160 to EUR170 million for the current fiscal year. Guidance for Total Revenue: EUR170 to EUR180 million for the current fiscal year. Warning!
Show less
Read more
Impact Snapshot
Event Time:
VALN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VALN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VALN alerts
High impacting Valneva SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
VALN
News
- Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 [Yahoo! Finance]Yahoo! Finance
- Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2GlobeNewswire
- Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare ConferencesGlobeNewswire
- Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate UpdatesGlobeNewswire
- Valneva SE (VALN) Q3 2024 Earnings Report Preview: What to Look For [Yahoo! Finance]Yahoo! Finance
VALN
Analyst Actions
- 9/3/24 - HC Wainwright
VALN
Sec Filings
- 11/13/24 - Form 6-K
- 11/7/24 - Form 6-K
- 10/21/24 - Form 6-K
- VALN's page on the SEC website